Apyx Medical Corporation (NASDAQ:APYX) finished Thursday with an addition of $0.86 to close at $5.06, an upside of 20.33 percent. An average of 578,916 shares of common stock have been traded in the last five days. There was a gain of $0.26 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 307,879 shares traded, while the 50-day average volume stands at 305,900.
APYX stock has decreased by -16.64% in the last month. The company shares reached their 1-month lowest point of $3.56 on 08/11/23. With the stock rallying to its 52-week high on 06/28/23, shares of the company touched a low of $1.31 and a high of $11.15 in 52 weeks. It has reached a new high 26 times so far this year and achieved 116.24% or $2.68 in price. In spite of this, the price is down -54.64% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
APYX stock investors should be aware that Apyx Medical Corporation (APYX) stock had its last reported insider trading activity 46 days ago on Jun 26.
Valuation Metrics
Apyx Medical Corporation (APYX) stock’s beta is 1.22. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.40, the price-to-book (PB) ratio at 4.87.
Financial Health
The quick ratio of Apyx Medical Corporation for the three months ended June 29 was 2.30, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.25 for the quarter ending June 29. Apyx Medical Corporation’s EBITDA margin for the year ending June 29 is -50.94%, while its operating margin for the same period stands at -52.90%. Its gross profit as reported stood at $29.13 million compared to revenue of $44.51 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$3.48 million in the quarter, while revenues were shrunk -70.98%. The analyst consensus anticipated Apyx Medical Corporation’s latest quarter earnings to come in at -$0.07 per share, but it turned out to be -$0.11, a -57.10% surprise. For the quarter, EBITDA amounted to -$5.41 million. Shareholders own equity worth $34.6 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Apyx Medical Corporation (APYX) price momentum. RSI 9-day as of the close on 10 August was 49.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 114.15%.
As of today, APYX’s price is $4.53 +5.46% or $0.26 from its 5-day moving average. APYX is currently trading -16.89% lower than its 20-day SMA and +100.00% higher than its 100-day SMA. However, the stock’s current price level is -20.70% below the SMA50 and +17.84% above the SMA200.
The stochastic %K and %D were 28.78% and 15.30%, respectively, and the average true range (ATR) was 0.59. With the 14-day stochastic at 64.60% and the average true range at 0.56, the RSI (14) stands at 46.65%. The stock has reached -0.32 on the 9-day MACD Oscillator while the 14-day reading was at -0.38.
Analyst Ratings
Stephens launched coverage on Apyx Medical Corporation (NASDAQ: APYX) in its analyst report released on July 14, 2023. The firm assigned the stock an Overweight rating. The consensus rating for Apyx Medical Corporation (APYX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell APYX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is APYX’s price target for the next 12 months?
Analysts predict a range of price targets between $4.50 and $10.00, with a median target of $8.50. Taking a look at these predictions, the average price target given by analysts for Apyx Medical Corporation (APYX) stock is $7.88.
